NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) reported results from its Phase 2a study of PF-06651600, an oral Janus kinase 3 inhibitor, and PF-06700841, a tyrosine kinase 2/JAK1 inhibitor, compared to placebo, in patients with moderate to severe alopecia areata. The company said both JAK inhibitors met the primary efficacy endpoint in improving hair regrowth on the scalp relative to baseline at week 24.
The company said, based on the totality of the data and the emerging clinical profiles, the investigational JAK3 inhibitor is advancing to the next phase of development for moderate to severe alopecia areata and will continue to be evaluated for rheumatoid arthritis, Crohn's disease and ulcerative colitis. PF-06700841 will continue to be evaluated for psoriasis, Crohn's disease and ulcerative colitis.
Copyright RTT News/dpa-AFX